Exelixis, Inc. (EXEL)
59.01
-0.12
(-0.20%)
USD |
NASDAQ |
Sep 04, 16:00
58.99
-0.02
(-0.03%)
After-Hours: 20:00
Exelixis SG&A Expense (TTM) : 533.92M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 533.92M |
| March 31, 2026 | 521.15M |
| December 31, 2025 | 518.73M |
| September 30, 2025 | 530.03M |
| June 30, 2025 | 518.17M |
| March 31, 2025 | 515.33M |
| December 31, 2024 | 492.13M |
| September 30, 2024 | 489.24M |
| June 30, 2024 | 515.58M |
| March 31, 2024 | 525.29M |
| December 31, 2023 | 542.70M |
| September 30, 2023 | 530.52M |
| June 30, 2023 | 507.35M |
| March 31, 2023 | 488.39M |
| December 31, 2022 | 459.86M |
| September 30, 2022 | 439.92M |
| June 30, 2022 | 426.49M |
| March 31, 2022 | 402.23M |
| December 31, 2021 | 401.72M |
| September 30, 2021 | 384.84M |
| June 30, 2021 | 371.47M |
| March 31, 2021 | 332.77M |
| December 31, 2020 | 293.36M |
| September 30, 2020 | 268.94M |
| June 30, 2020 | 232.02M |
| Date | Value |
|---|---|
| March 31, 2020 | 231.05M |
| December 31, 2019 | 228.24M |
| September 30, 2019 | 222.60M |
| June 30, 2019 | 219.45M |
| March 31, 2019 | 212.49M |
| December 31, 2018 | 204.99M |
| September 30, 2018 | 198.86M |
| June 30, 2018 | 188.87M |
| March 31, 2018 | 177.74M |
| December 31, 2017 | 159.39M |
| September 30, 2017 | 126.15M |
| June 30, 2017 | 120.48M |
| March 31, 2017 | 115.58M |
| December 31, 2016 | 116.14M |
| September 30, 2016 | 120.29M |
| June 30, 2016 | 105.66M |
| March 31, 2016 | 82.63M |
| December 31, 2015 | 57.30M |
| September 30, 2015 | 49.93M |
| June 30, 2015 | 41.99M |
| March 31, 2015 | 45.67M |
| December 31, 2014 | 50.83M |
| September 30, 2014 | 54.70M |
| June 30, 2014 | 58.39M |
| March 31, 2014 | 55.10M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| BioMarin Pharmaceutical, Inc. | 1.368B |
| Cytokinetics, Inc. | 370.47M |
| Emergent BioSolutions, Inc. | 181.20M |
| Gilead Sciences, Inc. | 9.147B |